www.fdanews.com/articles/68278-agendia-obtains-european-rights-to-arcturus-tuo-gene-profile
Agendia Obtains European Rights to Arcturus TUO-gene Profile
February 2, 2005
Agendia and Arcturus have signed a license agreement under which Agendia obtained the exclusive European rights to the TUO-gene expression profile (Tumor of Unknown Origin) discovered by Arcturus. Using this profile, Agendia has developed CupPrint, a gene expression-based diagnostic test to be used with patients diagnosed with Cancer Unknown Primary. Financial details of the agreement were not disclosed.
ArriveNet